In Massachusetts, Xenetic Biosciences, Inc. has a new Chief Scientific Officer, Curtis A. Lockshin. Lockshin’s experience with research and development in the biopharmaceutical industry and his various biomaterials, therapeutics and biosensors inventions and patents will come in handy in his new role at Xenetic, a biopharmaceutical company. Lockshin was formerly a CEO, or served in other executive roles, at SciVac Therapuetics, VBI Vaccines, Guardum Pharmaceuticals, and OPKO Health. Lockshin will help Xenetic with their focus on next-gen biologic drugs and oncology therapeutics. Scott Maguire, Chief Executive Officer of Xenetic said in their press release “With our second important executive level appointment since our Nasdaq listing, Xenetic now has a structure to deliver on what we believe will be a transformational 2017.”
Latest article
Fishway hooks Multus to jointly accelerate cultivated fish
In the United Kingdom, Fishway and Multus Biotechnology have partnered to bring cultivated fish to market faster.
The pact will leverage Fishway's expertise in...
Pirelli unveils biobased tires for Range Rovers
In Milan, tire manufacturer Pirelli has launched the first standard production tire for the global market made with over 70% biobased and recycled materials,...
MIT students design 3D printer that converts home food waste into knick-knacks
In Boston, Massachusetts Institute of Technology students Biru Cao and Qiqing Wang have developed an AI-drive desktop 3D printer that converts household food waste...